Why the study?
Takotsubo cardiomyopathy can predispose patients to significant long-term morbidity and mortality, but literature regarding long-term clinical outcomes in these patients is limited.
What clinical, biochemical, and imaging factors predict MACE and mortality in patients with Takotsubo cardiomyopathy?
Population
6443 patients with Takotsubo cardiomyopathy across 19 studies
Comparison
Clinical, biochemical, and imaging factors associated with MACE and mortality
Design
Systematic review and meta-analysis
Key result
Killip-Kimball class >1 was a strong predictor of major adverse cardiovascular events in Takotsubo cardiomyopathy (OR 2.216; 95% CI 1.673-2.936; P<0.001), alongside dyspnoea and secondary TCM.
Authors
Loading...
Dyspnea, Killip-Kimball class >1, secondary TCM, right ventricular involvement, physical stressors, and diabetes are significant predictors of long-term MACE and mortality in patients with Takotsubo cardiomyopathy.
Meta-Analysis (n=6,443)
What clinical, biochemical, and imaging factors predict MACE and mortality in patients with Takotsubo cardiomyopathy?
Odds Ratio: 2.216 (95% CI 1.673–2.936)
p-value: p=<0.001
Dyspnea, Killip-Kimball class >1, secondary TCM, right ventricular involvement, physical stressors, and diabetes are significant predictors of long-term MACE and mortality in patients with Takotsubo cardiomyopathy.
Jirjis et al. (2025) conducted a meta-analysis in Takotsubo cardiomyopathy (n=6,443). Risk factors (Killip-Kimball class >1, dyspnoea, secondary TCM, right ventricular involvement) vs. Absence of these risk factors was evaluated on Major adverse cardiovascular events (MACE) (OR 2.216, 95% CI 1.673-2.936, p=<0.001). Killip-Kimball class >1 was a strong predictor of major adverse cardiovascular events in Takotsubo cardiomyopathy (OR 2.216; 95% CI 1.673-2.936; P<0.001), alongside dyspnoea and secondary TCM.